Synthetic Biologics Inc (SYN) 1.78 $SYN
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 4:00PM CDT
Synthetic Biologics (SYN) announced that the FDA has granted orphan drug designation to its SYN-005.
Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day
PR Newswire - Tue Sep 16, 9:35AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company's Investor Day in New York which highlighted its irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).
Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
PR Newswire - Fri Sep 12, 12:23PM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. In the U.S., Orphan Drug Designation provides a variety of incentives, including seven years of market exclusivity, should SYN-005 receive FDA approval for the treatment of Pertussis.
Synthetic Biologics to Host Phase II Trimesta(TM) for Multiple Sclerosis Conference Call
PR Newswire - Thu Sep 11, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host a an investor conference call on Friday, September 12, 2014, at 9:15 a.m. EDT. The conference call will highlight TrimestaTM, the Company's oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), immediately following the oral presentation at 8:39 a.m. EDT by lead academic investigator, Rhonda Voskuhl, M.D., at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston.
Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day
PR Newswire - Wed Sep 10, 11:04AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that its Investor Day to highlight the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS), will be webcast live at 9:00 a.m. EDT on Tuesday, September 16, 2014.
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
PR Newswire - Mon Sep 08, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that data from its novel SYN-005 program for the treatment of Pertussis were highlighted in an oral presentation on September 7th by Jennifer Maynard, Ph.D., at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. SYN-005 combines two highly synergistic humanized monoclonal antibodies (mAbs) designed to target and neutralize pertussis toxin.
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
PR Newswire - Sun Sep 07, 7:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today preclinical data that further validate the Company's novel approach to preventing Clostridium difficile (C. difficile). The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it has surpassed MRSA as the number one hospital-acquired infection in the United States. The data were highlighted on September 6th at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), in Washington, D.C.
Synthetic Biologics to begin SYN-004's clinical trial in 4Q 2014 to prevent C. difficile infections
M2 - Wed Sep 03, 6:53AM CDT
Biotechnology company Synthetic Biologics (NYSE MKT:SYN) said on Tuesday that it has received encouraging results from its final preclinical toxicology study of SYN-004 to prevent the devastating effects of Clostridium difficile (C. difficile) under the US Food and Drug Administration (FDA) guidance.
Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
PR Newswire - Wed Sep 03, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday, September 9, 2014 at the New York Palace Hotel in New York City.
Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
PR Newswire - Tue Sep 02, 6:33AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. Per U.S. Food and Drug Administration (FDA) guidance, this bridging study was required to move the Company's lead anti-infective, second-generation product candidate designed to prevent the devastating effects of Clostridium difficile (C. difficile), toward the clinic.
Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile
PR Newswire - Thu Aug 28, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of SYN-004, Synthetic Biologics' proprietary oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infections.
Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014(TM)
PR Newswire - Tue Aug 26, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile), will be presented at the Infectious Disease Week (IDWeek 2014(TM)) held by the Infectious Diseases Society of America (IDSA), October 8-12, in Philadelphia, PA.
Synthetic Biologics (SYN) Jumps: Stock Adds 16% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 7:51AM CDT
Synthetic Biologics Inc. (SYN) was a big mover last session, as its shares rose 16% on the day.
Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
PR Newswire - Tue Aug 19, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel C. difficile development program will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
PR Newswire - Thu Aug 14, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three and six months ended June 30, 2014, and provided an operational progress update.
Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day
PR Newswire - Wed Aug 13, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
PR Newswire - Tue Aug 12, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.
Synthetic Biologics to Report Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the three and six months ended June 30, 2014 on Thursday, August 14, 2014. The Company will hold an investor conference call on Thursday, August 14, at 8:30 am EDT.
Synthetic Biologics' SYN-005 Gets Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 4:00PM CDT
Synthetic Biologics (SYN) announced that the FDA has granted orphan drug designation to its SYN-005.
Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day
PR Newswire - Tue Sep 16, 9:35AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today the completion of the Company's Investor Day in New York which highlighted its irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).
Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
PR Newswire - Fri Sep 12, 12:23PM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. In the U.S., Orphan Drug Designation provides a variety of incentives, including seven years of market exclusivity, should SYN-005 receive FDA approval for the treatment of Pertussis.
Synthetic Biologics to Host Phase II Trimesta(TM) for Multiple Sclerosis Conference Call
PR Newswire - Thu Sep 11, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host a an investor conference call on Friday, September 12, 2014, at 9:15 a.m. EDT. The conference call will highlight TrimestaTM, the Company's oral product candidate for the treatment of relapsing-remitting multiple sclerosis (MS), immediately following the oral presentation at 8:39 a.m. EDT by lead academic investigator, Rhonda Voskuhl, M.D., at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston.
Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day
PR Newswire - Wed Sep 10, 11:04AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that its Investor Day to highlight the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS), will be webcast live at 9:00 a.m. EDT on Tuesday, September 16, 2014.
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals
PR Newswire - Mon Sep 08, 8:15AM CDT
On Friday, September 05, 2014, the NASDAQ Composite ended at 4,582.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.40% higher at 17,137.36, and the S&P 500 closed at 2,007.71, up 0.50%. The gains were broad based as all the ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 741.23, up 0.57%, and the index has advanced 5.89% in the last one month. Investor-Edge has initiated coverage on the following equities: Celldex Therapeutics Inc. (NASDAQ: CLDX), Synthetic Biologics Inc. (NYSE MKT: SYN), Geron Corporation (NASDAQ: GERN), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX), and NPS Pharmaceuticals Inc. (NASDAQ: NPSP). Free research on these five companies can be accessed at:
Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
PR Newswire - Mon Sep 08, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that data from its novel SYN-005 program for the treatment of Pertussis were highlighted in an oral presentation on September 7th by Jennifer Maynard, Ph.D., at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. SYN-005 combines two highly synergistic humanized monoclonal antibodies (mAbs) designed to target and neutralize pertussis toxin.
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC
PR Newswire - Sun Sep 07, 7:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today preclinical data that further validate the Company's novel approach to preventing Clostridium difficile (C. difficile). The U.S. Centers for Disease Control has identified C. difficile as an "urgent public health threat," and it has surpassed MRSA as the number one hospital-acquired infection in the United States. The data were highlighted on September 6th at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), in Washington, D.C.
Synthetic Biologics to begin SYN-004's clinical trial in 4Q 2014 to prevent C. difficile infections
M2 - Wed Sep 03, 6:53AM CDT
Biotechnology company Synthetic Biologics (NYSE MKT:SYN) said on Tuesday that it has received encouraging results from its final preclinical toxicology study of SYN-004 to prevent the devastating effects of Clostridium difficile (C. difficile) under the US Food and Drug Administration (FDA) guidance.
Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City
PR Newswire - Wed Sep 03, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that Jeffrey Riley, CEO, is scheduled to present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday, September 9, 2014 at the New York Palace Hotel in New York City.
Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections
PR Newswire - Tue Sep 02, 6:33AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004. Per U.S. Food and Drug Administration (FDA) guidance, this bridging study was required to move the Company's lead anti-infective, second-generation product candidate designed to prevent the devastating effects of Clostridium difficile (C. difficile), toward the clinic.
Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile
PR Newswire - Thu Aug 28, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of SYN-004, Synthetic Biologics' proprietary oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infections.
Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014(TM)
PR Newswire - Tue Aug 26, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile), will be presented at the Infectious Disease Week (IDWeek 2014(TM)) held by the Infectious Diseases Society of America (IDSA), October 8-12, in Philadelphia, PA.
Synthetic Biologics (SYN) Jumps: Stock Adds 16% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 7:51AM CDT
Synthetic Biologics Inc. (SYN) was a big mover last session, as its shares rose 16% on the day.
Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
PR Newswire - Tue Aug 19, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel C. difficile development program will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.
Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights
PR Newswire - Thu Aug 14, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, today reported financial results for the three and six months ended June 30, 2014, and provided an operational progress update.
Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day
PR Newswire - Wed Aug 13, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC
PR Newswire - Tue Aug 12, 5:58AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, in Washington D.C.
Synthetic Biologics to Report Second Quarter 2014 Financial Results
PR Newswire - Thu Aug 07, 5:56AM CDT
Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it intends to release its financial results for the three and six months ended June 30, 2014 on Thursday, August 14, 2014. The Company will hold an investor conference call on Thursday, August 14, at 8:30 am EDT.
